# Bernhard Hemmer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/471682/publications.pdf

Version: 2024-02-01

| | | 3151 | 3822 |
|---|---|---|---|
| 401 | 37,960 | 92 | 178 |
| papers | citations | h-index | g-index |

| | | | |
|---|---|---|---|
| 439 | 439 | 439 | 34731 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms. Multiple Sclerosis Journal, 2022, 28, 1020-1027. | 1.4 | 37 |
| 2 | Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Multiple Sclerosis Journal, 2022, 28, 132-138. | 1.4 | 31 |
| 3 | Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2022, 28, 522-531. | 1.4 | 24 |
| 4 | Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. Multiple Sclerosis Journal, 2022, 28, 900-909. | 1.4 | 4 |
| 5 | COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 3.1 | 26 |
| 6 | Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 3.1 | 13 |
| 7 | Intrathecally Expanding B Cell Clones in Herpes Simplex Encephalitis: A Case Report. Neurology and Therapy, 2022, , 1. | 1.4 | 2 |
| 8 | A new form of axonal pathology in a spinal model of neuromyelitis optica. Brain, 2022, 145, 1726-1742. | 3.7 | 10 |
| 9 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456. | 1.4 | 16 |
| 10 | Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 3.1 | 13 |
| 11 | Association of pregnancies with risk of multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1630-1640. | 1.4 | 2 |
| 12 | Cryptococcal Meningitis Reported With Fingolimod Treatment. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 3.1 | 11 |
| 13 | Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies. Multiple Sclerosis and Related Disorders, 2022, 60, 103728. | 0.9 | 1 |
| 14 | Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability. NeuroImage: Clinical, 2022, 34, 103006. | 1.4 | 11 |
| 15 | The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. Neurology, 2022, 99, . | 1.5 | 21 |
| 16 | From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology, 2022, 18, 559-572. | 4.9 | 23 |
| 17 | P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica. Neurotherapeutics, 2022, 19, 1603-1616. | 2.1 | 3 |
| 18 | T1-Weighted Intensity Increase After aÂSingle Administration of aÂLinear Gadolinium-Based Contrast Agent in Multiple Sclerosis. Clinical Neuroradiology, 2021, 31, 235-243. | 1.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics, 2021, 18, 364-377. | 2.1 | 20 |
| 20 | Genetic Variation in <scp>WNT9B</scp> Increases Relapse Hazard in Multiple Sclerosis. Annals of Neurology, 2021, 89, 884-894. | 2.8 | 12 |
| 21 | Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis. Neurology, 2021, 96, . | 1.5 | 20 |
| 22 | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110227. | 0.5 | 20 |
| 23 | Artificial intelligence extension of the OSCARâ€IB criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542. | 1.7 | 33 |
| 24 | Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 3.1 | 15 |
| 25 | Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. Nature Immunology, 2021, 22, 880-892. | 7.0 | 34 |
| 26 | The Aryl Hydrocarbon Receptorâ€"Dependent TGF-Î±/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 3.1 | 12 |
| 27 | Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1042. | 3.1 | 5 |
| 28 | Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1403-1410. | 1.4 | 12 |
| 29 | Association of peripapillary hyperâ€reflective ovoid masslike structures and disease duration in primary progressive multiple sclerosis. European Journal of Neurology, 2021, 28, . | 1.7 | 9 |
| 30 | Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. Neurological Research and Practice, 2021, 3, 45. | 1.0 | 7 |
| 31 | Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsingâ€"Remitting Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2589-2597. | 2.1 | 0 |
| 32 | Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772. | 4.9 | 261 |
| 33 | COVID-19-associated Large Vessel Stroke in aÂ28-year-old Patient. Clinical Neuroradiology, 2021, 31, 511-514. | 1.0 | 9 |
| 34 | Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 38 |
| 35 | Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 3.1 | 14 |
| 36 | Case Series: Acute Hemorrhagic Encephalomyelitis After SARS-CoV-2 Vaccination. Frontiers in Neurology, 2021, 12, 820049. | 1.1 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LCâ€“MS/MS. Nature Communications, 2020, 11, 157. | 5.8 | 218 |
| 38 | Genetic determinants of the humoral immune response in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e827. | 3.1 | 7 |
| 39 | Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-Î², glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. PLoS ONE, 2020, 15, e0235449. | 1.1 | 20 |
| 40 | Vaccination in B-cellâ€“depleted patients with multiple sclerosis. Neurology, 2020, 95, 613-614. | 1.5 | 5 |
| 41 | Code Stroke Patient Referral by Emergency Medical Services During the Public COVID-19 Pandemic Lockdown. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105175. | 0.7 | 13 |
| 42 | Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. Journal of the Neurological Sciences, 2020, 418, 117090. | 0.3 | 125 |
| 43 | Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses. Frontiers in Immunology, 2020, 11, 606338. | 2.2 | 42 |
| 44 | Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. BMC Medicine, 2020, 18, 298. | 2.3 | 11 |
| 45 | Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 681-686. | 0.9 | 66 |
| 46 | Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807. | 2.7 | 67 |
| 47 | Is APOE Îµ4 associated with cognitive performance in early MS?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e728. | 3.1 | 11 |
| 48 | Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063. | 1.4 | 21 |
| 49 | Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044. | 1.4 | 39 |
| 50 | Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis. European Journal of Neurology, 2020, 27, 2217-2224. | 1.7 | 21 |
| 51 | Treatment of MOG antibody associated disorders: results of an international survey. Journal of Neurology, 2020, 267, 3565-3577. | 1.8 | 64 |
| 52 | DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. PLoS Computational Biology, 2020, 16, e1007616. | 1.5 | 54 |
| 53 | Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy. Journal of Neurology, 2020, 267, 2307-2318. | 1.8 | 23 |
| 54 | Vitamin D, smoking, EBV, and long-term cognitive performance in MS. Neurology, 2020, 94, e1950-e1960. | 1.5 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A call for a global COVID-19 Neuro Research Coalition. Lancet Neurology, The, 2020, 19, 482-484. | 4.9 | 22 |
| 56 | Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain, 2020, 161, 787-796. | 2.0 | 29 |
| 57 | Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348. | 3.9 | 31 |
| 58 | A large case-control study on vaccination as risk factor for multiple sclerosis. Neurology, 2019, 93, e908-e916. | 1.5 | 31 |
| 59 | The neuropathology of fatal encephalomyelitis in human Borna virus infection. Acta Neuropathologica, 2019, 138, 653-665. | 3.9 | 57 |
| 60 | Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naÃ¯ve notion?. Brain and Behavior, 2019, 9, e01417. | 1.0 | 8 |
| 61 | Isolation, Culture and Functional Characterization of Glia and Endothelial Cells From Adult Pig Brain. Frontiers in Cellular Neuroscience, 2019, 13, 333. | 1.8 | 13 |
| 62 | Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, . | 6.0 | 710 |
| 63 | Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 92, 151.2-151. | 1.5 | 0 |
| 64 | Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 124-129. | 0.9 | 6 |
| 65 | Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197. | 4.9 | 110 |
| 66 | A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250. | 3.9 | 87 |
| 67 | CSF Protein Concentration Shows No Correlation With Brain Volume Measures. Frontiers in Neurology, 2019, 10, 463. | 1.1 | 1 |
| 68 | CSF parameters associated with early MRI activity in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e573. | 3.1 | 18 |
| 69 | A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nature Communications, 2019, 10, 2236. | 5.8 | 65 |
| 70 | Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging. NeuroImage: Clinical, 2019, 23, 101849. | 1.4 | 60 |
| 71 | Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984709. | 1.5 | 10 |
| 72 | Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurology, 2019, 76, 841. | 4.5 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opinion on Biological Therapy, 2019, 19, 829-843. | 1.4 | 34 |
| 74 | Plasma Levels of Soluble AÎ²PPÎ² as a Biomarker for Alzheimerâ€™s Disease with Dementia. Journal of Alzheimer's Disease, 2019, 69, 83-90. | 1.2 | 0 |
| 75 | Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629. | 2.8 | 104 |
| 76 | Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis. Radiology, 2019, 291, 429-435. | 3.6 | 46 |
| 77 | Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. Journal of Neuroinflammation, 2019, 16, 219. | 3.1 | 96 |
| 78 | Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27. | 1.1 | 22 |
| 79 | Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology, 2019, 266, 386-397. | 1.8 | 24 |
| 80 | Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Multiple Sclerosis Journal, 2019, 25, 565-573. | 1.4 | 9 |
| 81 | Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 661-668. | 1.4 | 12 |
| 82 | Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 224-234. | 1.4 | 104 |
| 83 | Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. JAMA Neurology, 2018, 75, 1071. | 4.5 | 72 |
| 84 | Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2018, 90, e1815-e1821. | 1.5 | 123 |
| 85 | <scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 2018, 25, 215-237. | 1.7 | 147 |
| 86 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120. | 1.4 | 458 |
| 87 | Multiple sclerosis. Lancet, The, 2018, 391, 1622-1636. | 6.3 | 1,204 |
| 88 | Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446. | 3.1 | 54 |
| 89 | Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603. | 1.4 | 101 |
| 90 | Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters. Multiple Sclerosis Journal, 2018, 24, 1115-1125. | 1.4 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients. Journal of Autoimmunity, 2018, 88, 83-90. | 3.0 | 11 |
| 92 | A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015. Frontiers in Neurology, 2018, 9, 871. | 1.1 | 33 |
| 93 | Apheresis therapies for NMOSD attacks. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e504. | 3.1 | 173 |
| 94 | Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7. | 13.5 | 115 |
| 95 | Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity. Nature Immunology, 2018, 19, 1341-1351. | 7.0 | 82 |
| 96 | Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876719. | 0.5 | 18 |
| 97 | DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. Nature Communications, 2018, 9, 2397. | 5.8 | 147 |
| 98 | Monocyte NOTCH2 expression predicts IFN-Î² immunogenicity in multiple sclerosis patients. JCI Insight, 2018, 3, . | 2.3 | 46 |
| 99 | Immune-directed therapies in MS â€" efficacy and limitations. Nature Reviews Neurology, 2017, 13, 72-74. | 4.9 | 10 |
| 100 | Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis. JAMA Neurology, 2017, 74, 847. | 4.5 | 38 |
| 101 | The spectrum of aseptic central nervous system infections in southern Germany â€“ demographic, clinical and laboratory findings. European Journal of Neurology, 2017, 24, 1062-1070. | 1.7 | 17 |
| 102 | Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647. | 0.9 | 123 |
| 103 | CNS Aquaporinâ€4â€specific B cells connect with multiple Bâ€cell compartments in neuromyelitis optica spectrum disorder. Annals of Clinical and Translational Neurology, 2017, 4, 369-380. | 1.7 | 53 |
| 104 | Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126. | 1.2 | 197 |
| 105 | Daclizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion on Biological Therapy, 2017, 17, 747-753. | 1.4 | 4 |
| 106 | Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234. | 13.9 | 1,322 |
| 107 | Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220. | 13.9 | 1,324 |
| 108 | Cortical pathology in multiple sclerosis detected by the <scp>T</scp>1/<scp>T</scp>2â€weighted ratio from routine magnetic resonance imaging. Annals of Neurology, 2017, 82, 519-529. | 2.8 | 102 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812. | 4.9 | 397 |
| 110 | Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1092-1103. | 1.4 | 60 |
| 111 | Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nature Immunology, 2017, 18, 74-85. | 7.0 | 311 |
| 112 | Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796. | 3.7 | 139 |
| 113 | Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients. PLoS ONE, 2017, 12, e0179590. | 1.1 | 53 |
| 114 | Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12, e0170395. | 1.1 | 34 |
| 115 | From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. Current Neuropharmacology, 2017, 15, 874-891. | 1.4 | 40 |
| 116 | Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e208. | 3.1 | 9 |
| 117 | Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2016, 73, 1089. | 4.5 | 92 |
| 118 | Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillainâ€“BarrÃ© syndrome. Journal of Neurology, 2016, 263, 2105-2113. | 1.8 | 17 |
| 119 | The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. Acta Neuropathologica, 2016, 132, 413-431. | 3.9 | 26 |
| 120 | The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology, 2016, 87, 978-987. | 1.5 | 109 |
| 121 | In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis opticaâ€related pathology. Annals of Neurology, 2016, 79, 794-805. | 2.8 | 45 |
| 122 | Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain, 2016, 139, 2855-2863. | 3.7 | 95 |
| 123 | Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. NeuroImage, 2016, 142, 188-197. | 2.1 | 81 |
| 124 | PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?. Neurology, 2016, 87, 440-441. | 1.5 | 45 |
| 125 | HLA Genetic Risk Burden in Multiple Sclerosis. JAMA Neurology, 2016, 73, 1500. | 4.5 | 8 |
| 126 | NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335. | 3.8 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678. | 4.7 | 133 |
| 128 | Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity. Journal of Neurology, 2016, 263, 1495-1502. | 1.8 | 91 |
| 129 | Spontaneous Cerebrospinal Fluid Leak With Venous Engorgement Mimicking a Contrast-Enhancing Cervical Mass. JAMA Neurology, 2016, 73, 886. | 4.5 | 1 |
| 130 | Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294. | 2.1 | 36 |
| 131 | Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology, 2016, 79, 206-216. | 2.8 | 315 |
| 132 | B cell-directed therapies in multiple sclerosis. Neurodegenerative Disease Management, 2016, 6, 37-47. | 1.2 | 30 |
| 133 | Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination. Multiple Sclerosis Journal, 2016, 22, 893-900. | 1.4 | 74 |
| 134 | Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. Multiple Sclerosis Journal, 2016, 22, 1192-1201. | 1.4 | 21 |
| 135 | Prevalence of neuropathic pain in early multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1224-1230. | 1.4 | 47 |
| 136 | Predictive value of transcranial evoked potentials during mechanical endovascular therapy for acute ischaemic stroke: a feasibility study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 598-603. | 0.9 | 18 |
| 137 | Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608. | 0.6 | 15 |
| 138 | Extensive Recruitment of Plasma Blasts to the Cerebrospinal Fluid in Toscana Virus Encephalitis. Open Forum Infectious Diseases, 2015, 2, ofv124. | 0.4 | 3 |
| 139 | The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Experimental Neurology, 2015, 265, 8-21. | 2.0 | 59 |
| 140 | Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Review of Clinical Immunology, 2015, 11, 93-108. | 1.3 | 16 |
| 141 | Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643. | 3.7 | 54 |
| 142 | Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis. Journal of Autoimmunity, 2015, 56, 34-44. | 3.0 | 46 |
| 143 | Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologiesâ€"conflicting results?. Multiple Sclerosis Journal, 2015, 21, 537-539. | 1.4 | 9 |
| 144 | Dimethyl fumarate in relapsingâ€"remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics, 2015, 15, 339-346. | 1.4 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. Journal of Neuroinflammation, 2015, 12, 19. | 3.1 | 48 |
| 146 | Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurology, The, 2015, 14, 406-419. | 4.9 | 455 |
| 147 | B lymphocytes in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e104. | 3.1 | 132 |
| 148 | Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113. | 9.4 | 312 |
| 149 | Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 875-884. | 1.4 | 50 |
| 150 | Adult-onset vanishing white matter disease as differential diagnosis of primary progressive multiple sclerosis: A case report. Multiple Sclerosis Journal, 2015, 21, 666-668. | 1.4 | 6 |
| 151 | Mobilization of CD133+ Progenitor Cells in Patients with Acute Cerebral Infarction. PLoS ONE, 2014, 9, e70796. | 1.1 | 8 |
| 152 | Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2014, 20, 882-888. | 1.4 | 18 |
| 153 | Biomarkers of treatment response in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 165-172. | 1.4 | 13 |
| 154 | Complex antibody profiling to predict clinical outcome in childhood ADS. Neurology, 2014, 83, 2200-2201. | 1.5 | 0 |
| 155 | Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology, 2014, 82, 470-473. | 1.5 | 45 |
| 156 | JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants. PLoS Pathogens, 2014, 10, e1004084. | 2.1 | 49 |
| 157 | The genetics of natalizumab hypersensitivity. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e52. | 3.1 | 2 |
| 158 | Spinal cord atrophy in early Huntington's disease. Annals of Clinical and Translational Neurology, 2014, 1, 302-306. | 1.7 | 3 |
| 159 | Intrathecal antiâ€•<scp>CD</scp> 20 efficiently depletes meningeal B cells in <scp>CNS</scp> autoimmunity. Annals of Clinical and Translational Neurology, 2014, 1, 490-496. | 1.7 | 23 |
| 160 | Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. Journal of Neurology, 2014, 261, 130-143. | 1.8 | 67 |
| 161 | IL-27 and IL-12 oppose pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1. Nature Communications, 2014, 5, 3770. | 5.8 | 90 |
| 162 | To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 271-279. | 1.4 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Imaging of pathological effects of aquaporin-4 specific antibodies ex vivo and in vivo. Journal of Neuroimmunology, 2014, 275, 100. | 1.1 | 0 |
| 164 | Sources and functional significance of IL-6 in shaping autoreactive T cell responses in the peripheral immune compartment and the CNS. Journal of Neuroimmunology, 2014, 275, 152. | 1.1 | 0 |
| 165 | Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene. American Journal of Pathology, 2014, 184, 2420-2429. | 1.9 | 8 |
| 166 | Î±4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathologica Communications, 2014, 2, 27. | 2.4 | 25 |
| 167 | Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Annals of Neurology, 2014, 75, 810-828. | 2.8 | 41 |
| 168 | Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology, 2014, 175, 397-407. | 1.1 | 68 |
| 169 | Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology, 2014, 83, 1210-1216. | 1.5 | 30 |
| 170 | Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opinion on Biological Therapy, 2014, 14, 503-513. | 1.4 | 12 |
| 171 | Current and Future Therapies Targeting the Immune System in Multiple Sclerosis. Current Pharmaceutical Biotechnology, 2014, 15, 276-296. | 0.9 | 33 |
| 172 | The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2013, 10, 67. | 3.1 | 12 |
| 173 | Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2013, 70, 248. | 4.5 | 13 |
| 174 | Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. Journal of Neuroimmunology, 2013, 262, 19-26. | 1.1 | 10 |
| 175 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360. | 9.4 | 1,213 |
| 176 | Hunting for autoantibodies in multiple sclerosis. Neurology, 2013, 81, 944-945. | 1.5 | 3 |
| 177 | Mitochondrial membrane protein associated neurodegenration: A novel variant of neurodegeneration with brain iron accumulation. Movement Disorders, 2013, 28, 224-227. | 2.2 | 162 |
| 178 | Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. European Journal of Immunology, 2013, 43, 2078-2088. | 1.6 | 18 |
| 179 | Update on immunopathogenesis and immunotherapy in multiple sclerosis. ImmunoTargets and Therapy, 2013, 2, 21. | 2.7 | 17 |
| 180 | Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurology, The, 2013, 12, 756-767. | 4.9 | 205 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. American Journal of Human Genetics, 2013, 92, 854-865. | 2.6 | 164 |
| 182 | Enriched CD161<sup>high</sup>CCR6<sup>+</sup>Î³Î´ T Cells in the Cerebrospinal Fluid of Patients With Multiple Sclerosis. JAMA Neurology, 2013, 70, 345. | 4.5 | 69 |
| 183 | Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab â€œinfusion groupâ€• Multiple Sclerosis Journal, 2013, 19, 1213-1215. | 1.4 | 11 |
| 184 | Reply to Dr Pandey. Annals of Neurology, 2013, 73, 148-149. | 2.8 | 0 |
| 185 | Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1454-1461. | 1.4 | 37 |
| 186 | Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 2013, 19, 1533-1538. | 1.4 | 92 |
| 187 | Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Annals of Neurology, 2013, 73, 86-94. | 2.8 | 38 |
| 188 | White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Multiple Sclerosis Journal, 2013, 19, 1485-1492. | 1.4 | 49 |
| 189 | Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809. | 1.4 | 133 |
| 190 | Simultaneous Electroencephalographic and Functional Magnetic Resonance Imaging Indicate Impaired Cortical Topâ€“Down Processing in Association with Anesthetic-induced Unconsciousness. Anesthesiology, 2013, 119, 1031-1042. | 1.3 | 153 |
| 191 | Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. Neuropsychiatric Disease and Treatment, 2013, 9, 1339. | 1.0 | 14 |
| 192 | MRI Plaque Imaging Detects Carotid Plaques with a High Risk for Future Cerebrovascular Events in Asymptomatic Patients. PLoS ONE, 2013, 8, e67927. | 1.1 | 41 |
| 193 | The Role of B Cells in Multiple Sclerosis. , 2013, , 95-114. | | 0 |
| 194 | Anti-JC-virus antibody prevalence in a German MS cohort. Multiple Sclerosis Journal, 2012, 18, 1054-1055. | 1.4 | 13 |
| 195 | Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?. Neurology, 2012, 78, 928-930. | 1.5 | 40 |
| 196 | Time to talk about timing â€“ when to start, stop and change anti-migratory drugs in MS. Multiple Sclerosis Journal, 2012, 18, 1514-1516. | 1.4 | 2 |
| 197 | Pearls & Oy-sters: Cerebral HSV-2 vasculitis presenting as hemorrhagic stroke followed by multifocal ischemia. Neurology, 2012, 78, e12-e15. | 1.5 | 16 |
| 198 | <sup>18</sup>F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions. Journal of Nuclear Medicine, 2012, 53, 1269-1276. | 2.8 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Neuromyelitis optica following human papillomavirus vaccination. Neurology, 2012, 79, 285-287. | 1.5 | 47 |
| 200 | Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. Multiple Sclerosis Journal, 2012, 18, 1045-1049. | 1.4 | 27 |
| 201 | Spatiotemporal Reconfiguration of Large-Scale Brain Functional Networks during Propofol-Induced Loss of Consciousness. Journal of Neuroscience, 2012, 32, 12832-12840. | 1.7 | 175 |
| 202 | Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. Current Pharmaceutical Design, 2012, 18, 209-219. | 0.9 | 48 |
| 203 | Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 115-123. | 13.9 | 314 |
| 204 | TNF-alpha induced NFÎºB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine, 2012, 57, 269-275. | 1.4 | 96 |
| 205 | Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. Cytokine, 2012, 58, 231-237. | 1.4 | 5 |
| 206 | CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. Journal of Neuroinflammation, 2012, 9, 93. | 3.1 | 190 |
| 207 | An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. NeuroImage, 2012, 59, 3774-3783. | 2.1 | 972 |
| 208 | Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-Î² therapy in multiple sclerosis patients. Pharmacogenomics Journal, 2012, 12, 238-245. | 0.9 | 43 |
| 209 | Cognitive impairment as unusual first manifestation in late-onset relapsingâ€“remitting multiple sclerosis. Acta Neurologica Belgica, 2012, 112, 307-309. | 0.5 | 1 |
| 210 | Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation, 2012, 9, 14. | 3.1 | 593 |
| 211 | Clinicopathological considerations in acute disseminated encephalomyelitis (ADEM): a fulminant case with favorable outcome. Journal of Neurology, 2012, 259, 753-755. | 1.8 | 2 |
| 212 | The role of the Epsteinâ€“Barr Virus receptor CD21 in Multiple Sclerosis. Journal of Neuroimmunology, 2012, 242, 47-51. | 1.1 | 7 |
| 213 | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219. | 13.7 | 2,400 |
| 214 | The role of antibodies in multiple sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 239-245. | 1.8 | 96 |
| 215 | Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain, Behavior, and Immunity, 2011, 25, 423-428. | 2.0 | 66 |
| 216 | Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Multiple Sclerosis International, 2011, 2011, 1-9. | 0.4 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Functional Characterization of Aquaporin-4 Specific T Cells: Towards a Model for Neuromyelitis Optica. PLoS ONE, 2011, 6, e16083. | 1.1 | 54 |
| 218 | No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 264-5. | 4.9 | 2 |
| 219 | Thyroid antibodies in aquaporin-4 antibody positive central nervous system autoimmunity and multiple sclerosis. Clinical Endocrinology, 2011, 75, 271-272. | 1.2 | 6 |
| 220 | More CLEC16A gene variants associated with multiple sclerosis. Acta Neurologica Scandinavica, 2011, 123, 400-406. | 1.0 | 24 |
| 221 | EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. European Journal of Human Genetics, 2011, 19, 465-471. | 1.4 | 74 |
| 222 | The increasing incidence and prevalence of female multiple sclerosisâ€"A critical analysis of potential environmental factors. Autoimmunity Reviews, 2011, 10, 495-502. | 2.5 | 174 |
| 223 | A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1428-1437. | 1.9 | 3 |
| 224 | Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology, 2011, 258, 1747-1762. | 1.8 | 47 |
| 225 | Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. Journal of Neuroinflammation, 2011, 8, 146. | 3.1 | 68 |
| 226 | Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG Oligonucleotide. Journal of Neuroinflammation, 2011, 8, 59. | 3.1 | 3 |
| 227 | Myoclonusâ€dystonia in 18p deletion syndrome. Movement Disorders, 2011, 26, 560-561. | 2.2 | 17 |
| 228 | Natalizumab and primary central nervous system lymphoma revisited. Annals of Neurology, 2011, 69, 1061-1062. | 2.8 | 1 |
| 229 | Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Annals of Neurology, 2011, 70, 520-520. | 2.8 | 53 |
| 230 | Systemic Thrombolysis in Ischemic Stroke After Recent Oral Surgery and Management of Oral Cavity Bleeding. Annals of Emergency Medicine, 2011, 57, 517-519. | 0.3 | 4 |
| 231 | Th17 lymphocytes traffic to the central nervous system independently of Î±4 integrin expression during EAE. Journal of Experimental Medicine, 2011, 208, 2465-2476. | 4.2 | 241 |
| 232 | Sibling disability risk at onset and during disease progression in familial multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1060-1066. | 1.4 | 5 |
| 233 | Influence of the HLA-DRB1 Genotype on Antibody Development to Interferon Beta in Multiple Sclerosis. Archives of Neurology, 2011, 68, 480. | 4.9 | 51 |
| 234 | Dynamics of Intracranial Venous Flow Patterns in Patients with Idiopathic Intracranial Hypertension. European Neurology, 2011, 66, 334-338. | 0.6 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology, 2011, 76, 1310-1315. | 1.5 | 270 |
| 236 | Role of statins in the treatment of multiple sclerosis: an update. Neurodegenerative Disease Management, 2011, 1, 109-114. | 1.2 | 1 |
| 237 | Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology, 2011, 76, 1214-1221. | 1.5 | 146 |
| 238 | Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta. Archives of Neurology, 2010, 67, 1095-101. | 4.9 | 23 |
| 239 | Î³Î´ T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism. Immunity, 2010, 33, 351-363. | 6.6 | 246 |
| 240 | The radiologically isolated syndrome: take action when the unexpected is uncovered?. Journal of Neurology, 2010, 257, 1602-1611. | 1.8 | 36 |
| 241 | Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology, The, 2010, 9, 740-750. | 4.9 | 188 |
| 242 | Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31. | 0.6 | 86 |
| 243 | Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. Journal of Neuroimmunology, 2010, 219, 1-7. | 1.1 | 82 |
| 244 | The antibody response to oligodendrocyte specific protein in multiple sclerosis. Journal of Neuroimmunology, 2010, 221, 81-86. | 1.1 | 9 |
| 245 | Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. Journal of Neuroimmunology, 2010, 227, 162-166. | 1.1 | 69 |
| 246 | Prognostic value of the ABCD2score beyond short-term follow-up after transient ischemic attack (TIA) - a cohort study. BMC Neurology, 2010, 10, 50. | 0.8 | 18 |
| 247 | Acyclovir resistance in herpes simplex encephalitis. Annals of Neurology, 2010, 67, 830-833. | 2.8 | 58 |
| 248 | MRI plaque imaging reveals high-risk carotid plaques especially in diabetic patients irrespective of the degree of stenosis. BMC Medical Imaging, 2010, 10, 27. | 1.4 | 38 |
| 249 | Patent foramen ovale is not associated with an increased risk of stroke recurrence. European Journal of Neurology, 2010, 17, 1339-1345. | 1.7 | 16 |
| 250 | EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology, 2010, 17, 1019-1032. | 1.7 | 376 |
| 251 | IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity, 2010, 11, 397-405. | 2.2 | 70 |
| 252 | Boxing. Deutsches Ärzteblatt International, 2010, 107, 835-9. | 0.6 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Short commentary on â€˜a consensus protocol for the standardization of cerebrospinal fluid collection and biobankingâ€™. Multiple Sclerosis Journal, 2010, 16, 129-132. | 1.4 | 7 |
| 254 | Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology, 2010, 74, 1711-1715. | 1.5 | 54 |
| 255 | Natalizumab and Progressive Multifocal Leukoencephalopathy. Archives of Neurology, 2010, 67, 923-30. | 4.9 | 105 |
| 256 | EASY-HIT: HIV Full-Replication Technology for Broad Discovery of Multiple Classes of HIV Inhibitors. Antimicrobial Agents and Chemotherapy, 2010, 54, 5257-5268. | 1.4 | 35 |
| 257 | Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1189-1192. | 1.4 | 24 |
| 258 | Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12. | 0.1 | 3 |
| 259 | Active Immunization with Amyloid-Î² 1â€“42 Impairs Memory Performance through TLR2/4-Dependent Activation of the Innate Immune System. Journal of Immunology, 2010, 185, 6338-6347. | 0.4 | 61 |
| 260 | Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology, 2010, 74, 1127-1135. | 1.5 | 172 |
| 261 | Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain, 2010, 133, 375-388. | 3.7 | 36 |
| 262 | Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1201-8. | 4.9 | 82 |
| 263 | Translational Research in Neurology and Neuroscience 2010. Archives of Neurology, 2010, 67, 1307-15. | 4.9 | 11 |
| 264 | Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International, 2010, 57, 662-667. | 1.9 | 15 |
| 265 | The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. Journal of Autoimmunity, 2010, 34, 371-379. | 3.0 | 121 |
| 266 | The Combination of Interferonâ€Beta and HMGâ€CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?. CNS Neuroscience and Therapeutics, 2010, 16, 362-373. | 1.9 | 26 |
| 267 | Repetitive Pertussis Toxin Promotes Development of Regulatory T Cells and Prevents Central Nervous System Autoimmune Disease. PLoS ONE, 2010, 5, e16009. | 1.1 | 24 |
| 268 | Cooperation of B Cells and T Cells in the Pathogenesis of Multiple Sclerosis. Results and Problems in Cell Differentiation, 2009, 51, 115-126. | 0.2 | 44 |
| 269 | Should we measure the bioavailability of interferon Î² in vivo in patients with multiple sclerosis?. Nature Reviews Neurology, 2009, 5, 126-127. | 4.9 | 3 |
| 270 | Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology, 2009, 72, 396-401. | 1.5 | 128 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2009, 66, 259-61. | 4.9 | 38 |
| 272 | Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab. Archives of Neurology, 2009, 66, 1016-20. | 4.9 | 66 |
| 273 | INTERFERON BETA TREATMENT DOES NOT INDUCE ORGAN-SPECIFIC AUTOANTIBODIES IN MULTIPLE SCLEROSIS. Neurology, 2009, 73, 900-902. | 1.5 | 3 |
| 274 | A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology, 2009, 73, 1914-1922. | 1.5 | 653 |
| 275 | Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis. Archives of Neurology, 2009, 66, 1216. | 4.9 | 37 |
| 276 | Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of Disease, 2009, 35, 117-127. | 2.1 | 104 |
| 277 | Varicella zoster virus is not a diseaseâ€relevant antigen in multiple sclerosis. Annals of Neurology, 2009, 65, 474-479. | 2.8 | 52 |
| 278 | Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology, 2009, 66, 403-406. | 2.8 | 78 |
| 279 | Intrathecal pathogenic antiâ€“aquaporinâ€4 antibodies in early neuromyelitis optica. Annals of Neurology, 2009, 66, 617-629. | 2.8 | 516 |
| 280 | Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Annals of Neurology, 2009, 66, 833-842. | 2.8 | 283 |
| 281 | High-sensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. Journal of Neurology, 2009, 256, 783-791. | 1.8 | 26 |
| 282 | Free caspase activity in CSF of patients with dementia. Journal of Neurology, 2009, 256, 1561-1562. | 1.8 | 4 |
| 283 | The Value of the Serum Neurofilament Protein Heavy Chain as a Biomarker for Peri-operative Brain Injury After Carotid Endarterectomy. Neurochemical Research, 2009, 34, 1969-1974. | 1.6 | 12 |
| 284 | EFNS guidelines on diseaseâ€specific CSF investigations. European Journal of Neurology, 2009, 16, 760. | 1.7 | 73 |
| 285 | Lesion patterns in patients with cryptogenic stroke with and without rightâ€toâ€left shunt. European Journal of Neurology, 2009, 16, 1077-1082. | 1.7 | 23 |
| 286 | Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Research, 2009, 86, 82-88. | 0.8 | 108 |
| 287 | Surface expression of CXCR4 on circulating CD133+ progenitor cells is associated with plaque instability in subjects with carotid artery stenosis. Journal of Angiogenesis Research, 2009, 1, 10. | 2.9 | 8 |
| 288 | The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. International Journal of Neuropsychopharmacology, 2009, 12, 525. | 1.0 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Cerebral vasculitis mimicking migraine with aura in a patient with Crohn's disease. Acta Neurologica Belgica, 2009, 109, 44-8. | 0.5 | 10 |
| 290 | Lack of association between right-to-left shunt and cerebral ischemia after adjustment for gender and age. Journal of Negative Results in BioMedicine, 2008, 7, 7. | 1.4 | 7 |
| 291 | HLA-DRB1â^—0401 and HLA-DRB1â^—0408 Are Strongly Associated with the Development of Antibodies against Interferon-Î² Therapy in Multiple Sclerosis. American Journal of Human Genetics, 2008, 83, 219-227. | 2.6 | 114 |
| 292 | HLA-DRB10401 and HLA-DRB10408 Are Strongly Associated with the Development of Antibodies against Interferon-Î² Therapy in Multiple Sclerosis. American Journal of Human Genetics, 2008, 83, 541. | 2.6 | 0 |
| 293 | F.36. Introduction of a Cell-based Assay Against Native Aquaporin-4-High Specificity and Sensitivity for Neuromyelitis Optica. Clinical Immunology, 2008, 127, S54-S55. | 1.4 | 0 |
| 294 | Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clinical Immunology, 2008, 128, 306-313. | 1.4 | 13 |
| 295 | Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83. | 4.9 | 41 |
| 296 | Disease-Modifying Agents for Multiple Sclerosis. Drugs, 2008, 68, 2445-2468. | 4.9 | 63 |
| 297 | Effects of interferon-Î² on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-Î² treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 166-176. | 1.4 | 45 |
| 298 | NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Experimental Neurology, 2008, 211, 370-377. | 2.0 | 72 |
| 299 | Analysis of the Stathmin rs182455 Single Nucleotide Promoter Polymorphism in Patients with Multiple Sclerosis. Journal of Neurogenetics, 2008, 22, 181-186. | 0.6 | 3 |
| 300 | Persistence of Immunopathological and Radiological Traits in Multiple Sclerosis. Archives of Neurology, 2008, 65, 1527. | 4.9 | 40 |
| 301 | Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Archives of Neurology, 2008, 65, 1596. | 4.9 | 179 |
| 302 | Immunopathogenesis of Multiple Sclerosis. , 2007, , 197-204. | | 1 |
| 303 | Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain, 2007, 130, 2186-2198. | 3.7 | 47 |
| 304 | Revised criteria for neuromyelitis opticaâ€"a new diagnostic standard?. Nature Clinical Practice Neurology, 2007, 3, 132-133. | 2.7 | 7 |
| 305 | Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy. Archives of Neurology, 2007, 64, 169. | 4.9 | 65 |
| 306 | Acute disseminated encephalomyelitis: an acute hit against the brain. Current Opinion in Neurology, 2007, 20, 247-254. | 1.8 | 116 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | HIVâ€“hepatitis C virus co-infection is associated with decreased plasmatic IL-7 levels. Aids, 2007, 21, 253-255. | 1.0 | 14 |
| 308 | Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology, 2007, 20, 286-293. | 1.8 | 43 |
| 309 | High Incidence of Postâ€“Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes. Archives of Neurology, 2007, 64, 1055. | 4.9 | 2 |
| 310 | Impact of HMG-CoA reductase inhibition on brain pathology. Trends in Pharmacological Sciences, 2007, 28, 342-349. | 4.0 | 56 |
| 311 | Immunopathogenesis of Multiple Sclerosis: Overview. , 2007, , 171-187. | | 0 |
| 312 | Viral load determines the Bâ€cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Annals of Neurology, 2007, 62, 458-467. | 2.8 | 29 |
| 313 | Toward the development of rational therapies in multiple sclerosis: what is on the horizon?. Annals of Neurology, 2007, 62, 314-326. | 2.8 | 64 |
| 314 | Clonal expansions of CD4+ Bâ€„helper T cells in autoimmune myasthenia gravis. European Journal of Immunology, 2007, 37, 849-863. | 1.6 | 41 |
| 315 | The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis. Acta Neurologica Scandinavica, 2007, 116, 231-234. | 1.0 | 5 |
| 316 | CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. Journal of Neuroimmunology, 2007, 190, 72-79. | 1.1 | 115 |
| 317 | Neutralising antibodies to interferon Î² in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837. | 1.8 | 48 |
| 318 | Identification of Target Antigens in CNS Inflammation by Protein Array Technique. , 2007, , 137-148. | | 0 |
| 319 | Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain, 2006, 129, 200-211. | 3.7 | 485 |
| 320 | Immunopathogenesis and immunotherapy of multiple sclerosis. Nature Clinical Practice Neurology, 2006, 2, 201-211. | 2.7 | 224 |
| 321 | Central nervous system infections â€“ a potential complication of systemic immunotherapy. Current Opinion in Neurology, 2006, 19, 271-276. | 1.8 | 22 |
| 322 | High throughput analysis of TCR-Î² rearrangement and gene expression in single T cells. Laboratory Investigation, 2006, 86, 314-321. | 1.7 | 19 |
| 323 | A 32-year-old man with relapsing-progressive brainstem symptoms. Lancet Neurology, The, 2006, 5, 97-102. | 4.9 | 7 |
| 324 | Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist â€” A putative role for substance P in CNS inflammation. Journal of Neuroimmunology, 2006, 179, 1-8. | 1.1 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Accumulation of class switched IgDâ^'IgMâ^' memory B cells in the cerebrospinal fluid during neuroinflammation. Journal of Neuroimmunology, 2006, 180, 33-39. | 1.1 | 55 |
| 326 | Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of Neurology, 2006, 59, 743-747. | 2.8 | 414 |
| 327 | Lack of association with TorsinA haplotype in German patients with sporadic dystonia. Neurology, 2006, 66, 951-952. | 1.5 | 43 |
| 328 | Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1383. | 4.9 | 271 |
| 329 | Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19057-19062. | 3.3 | 213 |
| 330 | Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. Journal of Clinical Investigation, 2006, 116, 1037-1044. | 3.9 | 98 |
| 331 | Multiple sclerosis â€“ novel insights and new therapeutic strategies. Current Opinion in Neurology, 2005, 18, 211-220. | 1.8 | 34 |
| 332 | Characterizing the Mechanisms of Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1345. | 4.9 | 105 |
| 333 | Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurology, The, 2005, 4, 403-412. | 4.9 | 77 |
| 334 | Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Journal of Neuroimmunology, 2005, 168, 128-137. | 1.1 | 60 |
| 335 | Impact of the Asp299Gly polymorphism in the toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosis. Journal of Neuroimmunology, 2005, 165, 161-165. | 1.1 | 25 |
| 336 | High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: Implications for the initiation of autoimmune response in multiple sclerosis. Journal of Neuroimmunology, 2005, 169, 31-38. | 1.1 | 50 |
| 337 | A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology, 2005, 58, 50-57. | 2.8 | 203 |
| 338 | Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. Journal of Neurology, 2005, 252, v30-v37. | 1.8 | 12 |
| 339 | Acute Disseminated Encephalomyelitis. Archives of Neurology, 2005, 62, 1673. | 4.9 | 348 |
| 340 | Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 1620-3. | 4.9 | 124 |
| 341 | Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain, 2005, 128, 1667-1676. | 3.7 | 331 |
| 342 | Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. Journal of Clinical Investigation, 2005, 115, 1352-1360. | 3.9 | 248 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. Journal of Clinical Investigation, 2005, 115, 1352-1360. | 3.9 | 154 |
| 344 | Multiple Sclerosis - A Coordinated Immune Attack Across the Blood Brain Barrier. Current Neurovascular Research, 2004, 1, 141-150. | 0.4 | 38 |
| 345 | Recommendations for the Calculation of the Total Disturbing Return Current From Electric Traction Vehicles. IEEE Transactions on Power Delivery, 2004, 19, 1190-1197. | 2.9 | 29 |
| 346 | Viral Pathogens in Multiple Sclerosis. Archives of Neurology, 2004, 61, 1500. | 4.9 | 13 |
| 347 | Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis. Tissue Antigens, 2004, 64, 70-73. | 1.0 | 12 |
| 348 | The role of the Polio Virus Receptor and the Herpesvirus entry mediator B genes for the development of MS. Journal of Neuroimmunology, 2004, 156, 171-177. | 1.1 | 9 |
| 349 | Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathologica, 2004, 107, 575-577. | 3.9 | 16 |
| 350 | Escalating immunotherapy of multiple sclerosis. Journal of Neurology, 2004, 251, 1329-1339. | 1.8 | 129 |
| 351 | Myositis in a patient with large granular leukocyte leukemia. Muscle and Nerve, 2004, 29, 873-877. | 1.0 | 8 |
| 352 | Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle and Nerve, 2004, 30, 131-156. | 1.0 | 185 |
| 353 | Gene expression profiles derived from single cells in human postmortem brain. Brain Research Protocols, 2004, 13, 18-25. | 1.7 | 20 |
| 354 | Specificity and degeneracy: T cell recognition in CNS autoimmunity. Molecular Immunology, 2004, 40, 1057-1061. | 1.0 | 8 |
| 355 | Autosomal dominant congenital nystagmus is not linked to 6p12, 7p11, and 15q11 in a German family. American Journal of Ophthalmology, 2004, 138, 439-443. | 1.7 | 7 |
| 356 | New immunopathologic insights into multiple sclerosis. Current Neurology and Neuroscience Reports, 2003, 3, 246-255. | 2.0 | 27 |
| 357 | TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nature Immunology, 2003, 4, 248-254. | 7.0 | 426 |
| 358 | Clonal Accumulation of Activated CD8+T Cells in the Central Nervous System during the Early Phase of Neuroborreliosis. Journal of Infectious Diseases, 2003, 187, 963-973. | 1.9 | 27 |
| 359 | CD45 Isoform Expression in Autoimmune Myasthenia Gravis. Autoimmunity, 2003, 36, 117-121. | 1.2 | 17 |
| 360 | The Immune Response at Onset and During Recovery From Borrelia burgdorferi Meningoradiculitis. Archives of Neurology, 2003, 60, 849. | 4.9 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain, 2002, 125, 538-550. | 3.7 | 235 |
| 362 | Pathogenesis of multiple sclerosis: an update on immunology. Current Opinion in Neurology, 2002, 15, 227-231. | 1.8 | 116 |
| 363 | Human antibodies against amyloid Î² peptide: A potential treatment for Alzheimer's disease. Annals of Neurology, 2002, 52, 253-256. | 2.8 | 152 |
| 364 | Effect of minocycline in experimental autoimmune encephalomyelitis. Annals of Neurology, 2002, 52, 689-690. | 2.8 | 47 |
| 365 | A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics, 2002, 54, 158-163. | 1.2 | 35 |
| 366 | New concepts in the immunopathogenesis of multiple sclerosis. Nature Reviews Neuroscience, 2002, 3, 291-301. | 4.9 | 517 |
| 367 | Molecular Mimicry and Antigen-Specific T Cell Responses in Multiple Sclerosis and Chronic CNS Lyme Disease. Journal of Autoimmunity, 2001, 16, 187-192. | 3.0 | 61 |
| 368 | Immunosuppressive Treatment of Ocular Myasthenia Gravis. BioDrugs, 2001, 15, 369-378. | 2.2 | 18 |
| 369 | New approaches to dissect degeneracy and specificity in T cell antigen recognition. Journal of Molecular Medicine, 2001, 79, 358-367. | 1.7 | 14 |
| 370 | No association of three polymorphisms in the alpha-2-macroglobulin and lipoprotein related receptor genes with multiple sclerosis. Journal of Neuroimmunology, 2001, 118, 300-303. | 1.1 | 8 |
| 371 | Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain, 2001, 124, 2169-2176. | 3.7 | 210 |
| 372 | Combinatorial Peptide Libraries and Biometric Score Matrices Permit the Quantitative Analysis of Specific and Degenerate Interactions Between Clonotypic TCR and MHC Peptide Ligands. Journal of Immunology, 2001, 167, 2130-2141. | 0.4 | 97 |
| 373 | Decrypting the spectrum of antigen-specific T-cell responses: the avidity repertoire of MBP-specific T-cells. , 2000, 59, 86-93. | | 14 |
| 374 | A point mutation in PTPRC is associated with the development of multiple sclerosis. Nature Genetics, 2000, 26, 495-499. | 9.4 | 197 |
| 375 | Degeneracy in T-cell antigen recognition â€“ implications for the pathogenesis of autoimmune diseases. Journal of Neuroimmunology, 2000, 107, 148-153. | 1.1 | 18 |
| 376 | Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor VÎ² analysis. Journal of Immunological Methods, 2000, 246, 131-143. | 0.6 | 42 |
| 377 | Minimal peptide length requirements for CD4+ T cell clonesâ€”implications for molecular mimicry and T cell survival. International Immunology, 2000, 12, 375-383. | 1.8 | 70 |
| 378 | Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency. Journal of Immunology, 2000, 164, 861-871. | 0.4 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nature Medicine, 1999, 5, 1375-1382. | 15.2 | 216 |
| 380 | Molecular mimicry and multiple sclerosis: Degenerate T-cell recognition and the induction of autoimmunity. Annals of Neurology, 1999, 45, 559-567. | 2.8 | 98 |
| 381 | Stress doses of hydrocortisone reverse hyperdynamic septic shock. Critical Care Medicine, 1999, 27, 723-732. | 0.4 | 941 |
| 382 | From specificity to degeneracy to molecular mimicry: antigen recognition of human autoreactive and pathogen-specific CD4+ T cells. , 1999, , 21-28. | | 0 |
| 383 | Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events. Journal of Immunology, 1999, 162, 2073-80. | 0.4 | 88 |
| 384 | Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. Journal of Immunology, 1999, 163, 6424-34. | 0.4 | 48 |
| 385 | MRI of spinal cord and brain lesions in subacute combined degeneration. Neuroradiology, 1998, 40, 716-719. | 1.1 | 82 |
| 386 | Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Trends in Immunology, 1998, 19, 163-168. | 7.5 | 133 |
| 387 | Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. Journal of Neuroimmunology, 1998, 87, 203-209. | 1.1 | 59 |
| 388 | Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 822-827. | 0.9 | 198 |
| 389 | The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells. Chemical Biology and Drug Design, 1998, 52, 338-345. | 1.2 | 24 |
| 390 | Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. Journal of Immunology, 1998, 160, 3631-6. | 0.4 | 103 |
| 391 | Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. Journal of Immunology, 1998, 160, 5807-14. | 0.4 | 119 |
| 392 | Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class Iiâ€“restricted T Cell Clone. Journal of Experimental Medicine, 1997, 185, 1651-1660. | 4.2 | 313 |
| 393 | Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype. Neurology, 1997, 49, 1116-1126. | 1.5 | 40 |
| 394 | T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. Journal of Neuroimmunology, 1997, 77, 195-203. | 1.1 | 58 |
| 395 | Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. Journal of Immunology, 1997, 158, 2756-61. | 0.4 | 66 |
| 396 | Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. Journal of Immunology, 1997, 158, 3746-52. | 0.4 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. Journal of Immunology, 1997, 159, 1520-9. | 0.4 | 35 |
| 398 | Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87â€“99). European Journal of Immunology, 1996, 26, 2624-2634. | 1.6 | 96 |
| 399 | Human T lymphocytes specific for the immunodominant 83-99 epitope of myelin basic protein: Recognition of golli MBP HOG 7. , 1996, 45, 820-828. | | 16 |
| 400 | Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). , 1996, 45, 852-862. | | 41 |
| 401 | Restless legs syndrome after a borrelia-induced myelitis. Movement Disorders, 1995, 10, 521-522. | 2.2 | 26 |